Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference

CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
May 02, 2019 07:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results

— M281 Phase 2 trials in MG and HDFN active and enrolling patients — — Data supporting M281’s mechanism in HDFN, as first anti-FcRn antibody to inhibit maternal-fetal IgG transfer in perfusion model...
April 18, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
March 28, 2019 07:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019

CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
March 21, 2019 08:43 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta

Data supports M281’s potential to prevent placental transfer of disease-inducing antibodies from mother to fetus in alloimmune and autoimmune diseases of the fetus and newborn Global multi-center...
February 22, 2019 06:30 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

-- Ended 2018 with a cash position of $449.0 million -- -- Phase 2 trials of M281 in myasthenia gravis (MG) and hemolytic disease of the fetus and newborn (HDFN) underway; First healthy volunteer...
February 08, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
February 07, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting

Study highlights ability of M281 to inhibit transfer of immunoglobulin G from maternal to fetal circulation in ex vivo placental perfusion modelM281 currently being evaluated in an international Phase...
January 29, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G

CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
January 02, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that Craig Wheeler, President and CEO, will present at the 37th Annual J.P. Morgan...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right